Realistic net-prices and peak-patient-shares are key requirements for providing early commercial direction for assets whose clinical profile might not yet been finalised. Early to mid-stage commercial decision-making benefits from specialised tools that have been specifically developed for this purpose.
During the past year groupH developed an evidence-based Peak-Patient-Share tool (a.k.a. the Devil’s Advocate Tool) that was presented at the ephmra (European Pharmaceutical Market Research Association) Conference 2022.
The tool is now available and free-to-use on groupH’s website:
- ‘Devil’s Advocate’ Tool, allows for quick analysis of the pipeline and a high-level estimate of the peak share potential of new products.
The requirement for the tool and its methodology is described in a comprehensive and downloadable guide document – groupH ephmra Paper
Please contact us for any questions, clarifications or for a customised tutorial or webinar.